**4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**[Docket No. FDA-2020-N-0026]**

# Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Withdrawal

**AGENCY:** Food and Drug Administration, Health and Human Services (HHS).

**ACTION:** Notice; withdrawal.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing the notice that published in the *Federal Register* of September 30, 2021, that announced the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The *Federal Register* notice was published in error and is being withdrawn.

**FOR FURTHER INFORMATION CONTACT:** Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.

**SUPPLEMENTARY INFORMATION:** In the *Federal Register* of September 30, 2021 (86 FR 54219) in FR Doc. 2021-21311, FDA announced the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application for RETHYMIC (allogeneic processed thymus tissue-agdc), manufactured by Enzyvant Therapeutics, GmbH. The *Federal Register* notice was published in error and is being withdrawn.

Dated: October 1, 2021.

Lauren K. Roth,

Acting Principal Associate Commissioner for Policy.

[FR Doc. 2021-21823 Filed: 10/5/2021 8:45 am; Publication Date: 10/6/2021]